Navigation Links
Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovio's Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model
Date:7/18/2013

t results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended March 31, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceutica
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Varian Medical Systems to Exhibit Flat Panel Detectors, X-Ray Tubes and Imaging Software Optimized for Digital Radiography at CMEF
2. Varian Medical Systems to Exhibit Flat Panel Detectors, X-Ray Tubes and Imaging Software Optimized for Digital Radiography at MEDICA
3. Cerulean Pharma to Present Data on CRLX101s HIF-1a Inhibition at the American Association for Cancer Research Annual Meeting
4. CoMentis and Anvyl Announce Formation of Alpharmagen, a Joint Venture to explore Nicotinic Modulators
5. ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein
6. Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt
7. Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
8. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
9. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
10. Alphaport Named Winner of CorpUs Excellence and Innovation Award
11. Sophono Alpha 2 Hearing System Receives FDA Clearance for Use With MRI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: Global Coatings for ... This report analyzes the ... US$ Million by the following Product Segments: Active ... The report provides separate comprehensive analytics for the ...
(Date:8/20/2014)... SALT LAKE CITY , Aug. 20, 2014 /PRNewswire/ ... their revolutionary mobile diagnostic platform during a special event ... City, Utah , on September 5, 2014. The ... be LiveStreamed on the ApolloDx website, www.apollodx.com .  ... will transform diagnostic testing," said Jared Bauer , ...
(Date:8/20/2014)... , Aug. 20, 2014   Easy Breathe , the ... that its " Easy Blog " - has received more than ...   "We are thrilled that so many people are ... , CEO of Easy Breathe. "We,re committed to making sleep apnea ... Blog to stay informed about sleep apnea news , ...
Breaking Medicine Technology:Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 3Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 4
... - Nexavar is First Approved Systemic Therapy to ... EMERYVILLE, Calif., July 23 ,Bayer HealthCare Pharmaceuticals and ... New England Journal of Medicine published,results of a ... the absolute risk of death by 31 percent ...
... FluoroPharma Inc., a company developing,breakthrough molecular imaging ... positive Phase I results for BFPET, its novel,Fluorine-18 ... second cardiovascular product to complete Phase I clinical,development., ... to assess the blood flow in the,heart (myocardial ...
Cached Medicine Technology:The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... group of rhesus monkeys from deadly Marburg virus, a very ... percent of those it infects, researchers report. The drug ... even when it was given three days after infection, according ... Science Translational Medicine . This is the first drug ...
(Date:8/20/2014)... time to deploy Ebola vaccines is now, Free ... now, according to a commentary being published early online ... . The authors from Yale School of Public Health ... of the current Ebola outbreak represent a public health ... efforts. Several Ebola vaccines have been developed in the ...
(Date:8/20/2014)... By Dennis Thompson ... -- Regular exercise may help older women avoid a condition ... Physically active postmenopausal women had a 10 percent lower ... more sedentary, researchers report in the Aug. 20 issue of ... Active women enjoyed this protection against the heart rhythm disorder ...
(Date:8/20/2014)... is one of the most persistent and deadliest infectious ... people each year. , Scientists who study tuberculosis have ... likely spread from humans in Africa to seals and ... and transmitted it to Native people there before Europeans ... Genomes Reveal Seals as a Source of New World ...
(Date:8/20/2014)... found a novel approach to treating cancer - using ... of Science Translational Medicine shows that cancer ... by nerves that are linked to cancer stem cells. ... Botox made the treatment cheap, safe and efficient. The ... and will soon start testing on humans. , The ...
Breaking Medicine News(10 mins):Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 3Health News:News from Annals of Internal Medicine 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Treating gastric cancer -- with Botox 2
... ventilators, dialysis machines, agency says safety an issue, , ... ages and medical technology improves, more people are using ... at home, adding to the need for better-educated patients. ... and Drug Administration announced Tuesday that it has started ...
... D.C. Levels of epidermal growth factor receptor (EGFR) may ... prior to their breast cancer diagnosis, according to findings presented ... 2010, held here April 17-21. The goal of the ... of the Epidemiology Program at the Fred Hutchinson Cancer Research ...
... MA and Hyde Park, NY -- Responding to the health ... department of nutrition at Harvard School of Public Health (HSPH) ... sodium reduction strategies that are strong and effectiveand that maximize ... now overwhelming evidence that we must treat sodium reduction as ...
... who metabolize nicotine slowly may need to wear nicotine patch ... New research suggests that a set length of time for ... trying to kick the habit. , Researchers at the University ... people -- about three-quarters of smokers -- break down ...
... Deepak Srivastava, MD, director of the Gladstone Institute of ... UCSF, has been elected to the American Academy of ... W. Mahley as a member of the Academy. Established ... fathers, the Academy is one of the nation,s oldest ...
... ... Incentives Are Still Available , ... (Vocus) April 20, 2010 -- Toll Brothers, the nation,s leading builder of luxury homes, ... until May 2. With the slight rise in interest rates recently, and conventional wisdom pointing ...
Cached Medicine News:Health News:FDA Tightens Oversight of Home Medical Devices 2Health News:FDA Tightens Oversight of Home Medical Devices 3Health News:Increased EGFR levels may be an early marker of breast cancer 2Health News:Experts call for accelerated national sodium reduction initiatives 2Health News:Experts call for accelerated national sodium reduction initiatives 3Health News:Experts call for accelerated national sodium reduction initiatives 4Health News:Tailored Therapy May Help More Stop Smoking 2Health News:Gladstone's Deepak Srivastava elected to the American Academy of Arts and Sciences 2Health News:Spring Into A New Toll Brothers Dream Home During the National Spring Sales Event April 24 - May 2 2Health News:Spring Into A New Toll Brothers Dream Home During the National Spring Sales Event April 24 - May 2 3Health News:Spring Into A New Toll Brothers Dream Home During the National Spring Sales Event April 24 - May 2 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: